No conspiracy regarding recommendation for a group B meningococcus vaccine
| Autor: | Mary Ramsay, Andrew J. Pollard, Andrew Riordan |
|---|---|
| Rok vydání: | 2014 |
| Předmět: |
medicine.medical_specialty
Operations research Cost effectiveness business.industry Meningococcal Vaccines General Medicine Meningococcal vaccine Neisseria meningitidis Serogroup B Group B Meningococcal Infections Vaccination Policy decision Family medicine Humans Economic analysis Medicine Economic model business Meningococcus vaccine |
| Zdroj: | BMJ. 348:g2859-g2859 |
| ISSN: | 1756-1833 |
| DOI: | 10.1136/bmj.g2859 |
| Popis: | Isaacs and McVernon highlight the importance and complexity of policy decision making for a group B meningococcal vaccine based on cost effectiveness.1 The health economic analysis for a group B meningococcal vaccine is difficult because of uncertainties about critical parameters that determine whether the vaccine meets the required threshold for cost effectiveness. Indeed, the first health economic model made available to the independent scientific committee that advises the UK Departments of Health—the Joint Committee on Vaccination and … |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|